arrow
M

Mario Delia

azienda ospedaliero universitaria consorziale policlinico
H指数:28
被引数:2,901

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study

成人早期T细胞前体急性淋巴细胞白血病患者在接受儿科启发式GIMEMA LAL1913方案治疗后,早期同种异基因干细胞移植的积极结果。Campus ALL研究

2026-07-160
PRE
Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring

嵌合抗原受体-T细胞输注后的命运:细胞动力学与分子监测

2026-06-240
OAAI
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Hmpv in Haematological Malignancy, Insights From EpiCOVIDeha/Epiresha Registry

被低估、未接种疫苗、未治疗:一项关于血液系统恶性肿瘤患者Hmpv的多国登记分析,来自EpiCOVIDeha/Epiresha登记研究的见解

2026-02-270
OA
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

更正:RUNX1A异构体在急性髓系白血病中过度表达,并与FLT3内部串联重复突变相关。

2025-11-030
OAAI
Splenomegaly in de novo acute myeloid leukemia is associated with ASXL1 mutations together with a distinct clinical and gene expression profile

新诊断急性髓系白血病中的脾肿大与ASXL1突变相关,并伴有独特的临床和基因表达谱。

2025-10-230
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

RUNX1A异构体在急性髓系白血病中过表达,并与FLT3内部串联重复相关。

2025-07-150
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group
2024-10-280
PRE
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024-08-152
OAAI
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group
2024-08-080
PRE
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
2023-07-282
OAAI
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

新型冠状病毒肺炎血液系统恶性肿瘤患者的尼马曲韦/利托那韦: EPICOVIDEHA登记处的报告

2023-04-0123
OAAI
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
2023-03-245
PRE
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax
2023-02-098
OAAI